Amy Selly, CNP, AOCNP

home / authors / amy-selly-cnp-aocnp

Amy Selly, CNP, AOCNP, is the medical oncology advanced practice provider lead at Allina Health.

Articles

Supporting Cancer Survivors: The Clinician's Role

Supporting Cancer Survivors: The Clinician's Role

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses how physicians can support their patients' survivorship journeys.

Working With Underserved Populations of Cancer Survivors

Working With Underserved Populations of Cancer Survivors

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses the challenges facing cancer survivors from underserved populations.

The Role of Support in Cancer Survivorship

The Role of Support in Cancer Survivorship

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses the role support plays in the cancer survivor experience.

Challenges Facing Cancer Survivors

Challenges Facing Cancer Survivors

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses the varying challenges facing cancer patients and survivors.

Seeing Cancer as a Chronic Illness

Seeing Cancer as a Chronic Illness

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses how cancer as a chronic illness impacts definitions of survivorship.

Holistically Defining Cancer Survivorship

Holistically Defining Cancer Survivorship

Amy Selly, CNP, AOCNP
October 10th 2024

Amy Selly, CNP, AOCNP, discusses the different definitions of cancer survivorship.

Latest Updated Articles

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Published: November 13th 2024 | Updated: November 22nd 2024
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Published: August 18th 2023 | Updated: November 22nd 2024
Immunotherapy Options for an Older Patient With Metastatic Melanoma
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Published: October 19th 2024 | Updated: November 22nd 2024
Expert Takeaway From WCLC Congress Highlights Innovative ADC Showing Promise in SCLC
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
Published: June 6th 2024 | Updated: November 22nd 2024
Second-Line Targeted Options Considered in ESR1-Mutated Breast Cancer
The Targeted Pulse: Discover Upcoming Meetings, FDA Action, and Key Insights in SCLC and mCSPC
Published: November 17th 2024 | Updated: November 22nd 2024
The Targeted Pulse: Discover Upcoming Meetings, FDA Action, and Key Insights in SCLC and mCSPC